Life Sciences state of play
In the fast-moving world of medtech, biotech, and pharmaceuticals, directors and executives navigate a landscape defined by scientific complexity, regulatory scrutiny, and heightened stakeholder expectations.
These factors have led to a profound shift in how Directors & Officers (D&O) exposure is understood moving from a narrow insurance consideration to a broader reflection of governance, disclosure, and enterprise risk dynamics.
For leadership teams, this shift means not only recognising potential liabilities but also understanding how organisational decisions, communication practices, and oversight structures intersect with market and regulatory realities.
Increased D&O Liability exposure
At its core, D&O exposure arises when stakeholders, shareholders, regulators or third parties allege that a company’s leadership failed in their responsibilities.
In life sciences organisations, several factors tend to contribute to that exposure:
Clinical development milestones and setbacks: unexpected trial outcomes, late-breaking safety findings, or regulatory delays can prompt scrutiny of internal decision-making and public disclosures.
Capital markets pressures: frequent financing rounds, public trading, or valuation swings heighten attention on disclosure practices and risk management transparency.
Regulatory engagement: multinational regulatory frameworks and enforcement environments mean leaders are expected to understand and convey both compliance strategies and uncertainties.
Emerging technologies: digital transformation, AI, and data governance add layers of complexity to oversight expectations.
Importantly, these drivers highlight that D&O is not simply about insurance coverage; it is intertwined with how organisations present.
Trends shaping executive exposure
Several cross-cutting trends amplify D&O exposure for life sciences leadership:
Market and economic volatility: securities litigation and shareholder actions often follow periods of financial stress, adverse trial results, or volatile share performance environments common in biotech and medtech.
Regulatory complexity and enforcement focus: regulators across major jurisdictions are increasingly attentive to leadership conduct, especially in areas of product safety, advertising and promotional oversight, and compliance systems.
Cyber and data governance: boards are being examined for their role in overseeing digital risk, including cybersecurity and patient privacy and data. Gaps in oversight are emerging as focal points in related litigation trends.
Stakeholder expectations (ESG and transparency): expectations for transparency around governance, social impact, and environmental accountability have broadened what stakeholders perceive as relevant to leadership performance with implications for D&O exposure where expectations are unmet.
What leadership teams are observing in practice
Executives and boards in life sciences are increasingly focused on understanding D&O exposure through a broader lens by:
Linking disclosure practices with operational realities: clear articulation of uncertainty, particularly in scientific and regulatory pathways. This helps reduce ambiguity around expectations and can help align public communication with enterprise context.
Acknowledging governance oversight as part of organisational narrative: boards are placing increased emphasis on structures and processes that support oversight of key risk areas, including clinical strategy, regulatory compliance, and technology adoption.
Monitoring emerging external pressure points: stakeholders are paying attention not only to outcomes but to how leadership teams articulate and manage expectations around outcomes.
A framework for contextualising D&O exposure: For executives judging their own exposure landscape.
The following areas often serve as useful reference points:
Communication and disclosure practices: how are clinical uncertainties, regulatory contingencies, and strategic challenges reflected in stakeholder communications?
Governance processes: what mechanisms are in place for oversight of areas with high variability, such as development pipelines, emerging technologies, or M&A activities?
Stakeholder environment: how are investor expectations, advocacy dynamics, and regulatory enforcement trends evolving across key markets?
Seen through a holistic lens, rather than as isolated issues, these factors come together to reveal the broader forces shaping executive vulnerability.
How D&O Liability exposures emerge
Our experience tells us that D&O exposure in life sciences rarely arises from a single misstep or poor outcome.
More often, it crystallises through patterns that develop over time, how uncertainty is described across multiple disclosures, how evolving clinical or regulatory risks are contextualised for the market, and how consistent leadership messaging tracks underlying operational realities.
When outcomes later disappoint, it is this historical narrative, not the science itself, that external stakeholders, regulators, and plaintiff firms scrutinise most closely.
We also see that boards and executives are increasingly judged not only on decisions made, but on the quality of oversight evidenced along the way.
Claims and investigations frequently focus on whether material risks were actively interrogated, whether assumptions were challenged and documented, and whether disclosure language appropriately reflected the limits of knowledge at the time.
In this environment, D&O exposure becomes less about hindsight and more about how leadership teams demonstrate that uncertainty was understood, managed, and transparently communicated.
Ensuring D&O Liability Insurance is keeping up
For life sciences companies, D&O liability insurance is not a passive financial backstop but a governance-critical control that shapes how scrutiny is managed from the moment questions arise.
Ensuring both your broker and insurer are kept informed on material events for the company is essential to ensure the D&O Liability policy is keeping pace with the exposures of the company and its directors.
Claims and investigations frequently engage coverage issues early, often before formal allegations exist, and programs that are overly rigid, capacity-constrained, or dependent on insurer discretion can introduce friction at precisely the point directors and executives need speed, clarity, and independence. Designing D&O insurance around these realities, rather than treating it as a static annual purchase, has become an essential consideration for boards operating in this sector.
Concluding perspective
In life sciences, D&O exposure makes far more sense when viewed in the context of the wider organisational and external forces shaping leadership decisions.
For executives and boards, appreciating this interplay, informed by emerging litigation patterns, regulatory focus, and stakeholder expectations, contributes to a clearer perception of exposure and supports more robust organisational performance.
In an era where outcomes are uncertain and expectations are high, understanding D&O risk from a strategic vantage point is central to resilient leadership.
The contents of this publication are provided for general information only. Lockton arranges the insurance and is not the insurer. While the content contributors have taken reasonable care in compiling the information presented, we do not warrant that the information is correct. The contents of this publication are not intended as a legal commentary or advice and should not be relied on in that way. It is not intended to be interpreted as advice on which you should rely and may not necessarily be suitable for you. You must obtain professional or specialist advice before taking, or refraining from, any action based on the content in this publication.
© 2026 Lockton Companies Australia Pty Ltd.
